4 products found
C2N Diagnostics Products
-
PrecivityAD - Alzheimer’s Disease Blood Test
The PrecivityAD™ test is an innovative new blood test intended for use in patients with cognitive impairment. The test aims to help physicians better determine the presence or absence of amyloid plaques in the brain, a hallmark sign of Alzheimer’s ...
-
Model PrecivityAD2 - Blood Test
The PrecivityAD2™ blood test is intended for patients aged 55 and older with signs or symptoms of mild cognitive impairment or dementia, who are undergoing evaluation for Alzheimer’s disease or other causes of cognitive decline. A multi-analyte clinical diagnostic tool developed by C2N Diagnostics, the PrecivityAD2™ blood test aids healthcare providers in the detection of brain amyloid plaques, one of the neuropathological findings of ...
-
Model PrecivityAD - Blood Test
The PrecivityAD® Blood Test Answers Calls from Patients, Advocates, and Healthcare Providers Who Want Earlier Answers. Summary of Test and Patient Selection. The PrecivityAD® test identifies whether a patient is likely to have the presence or absence of amyloid plaques in the brain, a pathological hallmark of Alzheimer’s disease. The test relies on precise and robust quantitation of Amyloid Beta 42/40 ratio (Aβ 42/40) and detection of ...
-
Model ApoE - Genetic Testing
The PrecivityAD® test measures the concentrations of amyloid beta 42 and 40 (Aβ42 and Aβ40), as well as the presence of Apolipoprotein E (ApoE) isoforms in the blood. The test indicates if an individual is likely to have amyloid plaques in the brain, a hallmark of Alzheimer’s disease. ApoE4 genotype is a significant risk factor for brain amyloid accumulation and Alzheimer’s disease, and its incorporation into C2N’s ...